Published in Dig Dis Sci on November 01, 2009
Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2014) 3.38
Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut (2012) 2.00
Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ (2013) 1.58
Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. JAMA (2016) 1.52
Epidemiology of eosinophilic esophagitis. Gastroenterol Clin North Am (2014) 1.46
Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One (2012) 1.43
Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci (2011) 1.43
Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. Am J Gastroenterol (2010) 1.37
Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut (2015) 1.13
Temporal trends in the relative prevalence of dysphagia etiologies from 1999-2009. World J Gastroenterol (2012) 1.09
Practice patterns for the evaluation and treatment of eosinophilic oesophagitis. Aliment Pharmacol Ther (2010) 1.05
Bacterial infections in end-stage liver disease: current challenges and future directions. Gut (2012) 1.00
Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr (2013) 1.00
Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther (2012) 0.99
The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer (2014) 0.96
Acidic pH via NF-κB favours VEGF-C expression in human melanoma cells. Clin Exp Metastasis (2013) 0.96
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med (2016) 0.92
Use of proton pump inhibitors and subsequent risk of celiac disease. Dig Liver Dis (2013) 0.91
Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. PLoS One (2014) 0.89
Effects of Pantoprazole on Systemic and Gastric Pro- and Anti-inflammatory Cytokines in Critically Ill Patients. Iran J Pharm Res (2012) 0.88
Eosinophils in Gastrointestinal Disorders: Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am (2015) 0.87
Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. Gastroenterol Clin North Am (2014) 0.87
Can chronic gastritis cause an increase in fecal calprotectin concentrations? World J Gastroenterol (2010) 0.86
Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med (2015) 0.84
Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies. Nat Rev Gastroenterol Hepatol (2015) 0.83
Probe for the measurement of cell surface pH in vivo and ex vivo. Proc Natl Acad Sci U S A (2016) 0.82
Clinicopathologic Analysis of Proton Pump Inhibitor-Responsive Esophageal Eosinophilia in Korean Patients. Gut Liver (2016) 0.82
The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology (2016) 0.82
A possible involvement of Nrf2-mediated heme oxygenase-1 up-regulation in protective effect of the proton pump inhibitor pantoprazole against indomethacin-induced gastric damage in rats. BMC Gastroenterol (2012) 0.81
Eosinophilic esophagitis and proton pump inhibitors: controversies and implications for clinical practice. Gastroenterol Hepatol (N Y) (2014) 0.80
Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model. Neoplasia (2014) 0.79
Painful prosthesis: approaching the patient with persistent pain following total hip and knee arthroplasty. Clin Cases Miner Bone Metab (2013) 0.79
Idiopathic Pulmonary Fibrosis: Novel Concepts of Proton Pump Inhibitors as Antifibrotic Drugs. Am J Respir Crit Care Med (2016) 0.78
Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Med (2012) 0.78
Proton pump inhibitors for eosinophilic oesophagitis. Curr Opin Gastroenterol (2013) 0.78
Acid burn or cytokine sizzle in the pathogenesis of heartburn? J Gastroenterol Hepatol (2013) 0.77
Proton pump inhibitors and gastroenteritis. Eur J Epidemiol (2016) 0.77
Proton pump inhibitor-responsive oesophageal eosinophilia and eosinophilic oesophagitis: more similarities than differences. Curr Opin Gastroenterol (2015) 0.76
In vivo and in vitro protective effects of omeprazole against neuropathic pain. Sci Rep (2016) 0.76
Barrett's esophagus in 2016: From pathophysiology to treatment. World J Gastrointest Pharmacol Ther (2016) 0.76
Novel pH-Sensitive Cyclic Peptides. Sci Rep (2016) 0.75
Management of proton pump inhibitor responsive-esophageal eosinophilia and eosinophilic esophagitis: controversies in treatment approaches. Expert Rev Gastroenterol Hepatol (2015) 0.75
Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell Death Dis (2016) 0.75
Proton Pump Inhibitor-Induced Remission of Lymphocytic Esophagitis. ACG Case Rep J (2016) 0.75
Inhibition of gastric perception of mild distention by omeprazole in volunteers. World J Gastroenterol (2012) 0.75
Comparative evaluation of antimicrobial efficacy of triple antibiotic paste, calcium hydroxide, and a proton pump inhibitor against resistant root canal pathogens. Eur J Dent (2017) 0.75
Acid-suppressive Medications and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus(Gut 2014;63:1229-1237). J Neurogastroenterol Motil (2015) 0.75
Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006. J Clin Gastroenterol (2016) 0.75
Proton pump inhibitor prescription abuse and sepsis in cirrhosis. World J Gastrointest Pharmacol Ther (2016) 0.75
Improvement in Esophageal Distensibility in Response to Medical and Diet Therapy in Eosinophilic Esophagitis. Clin Transl Gastroenterol (2017) 0.75
Acid suppression therapy and allergic reactions. Allergo J Int (2015) 0.75
Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients. J Am Heart Assoc (2017) 0.75
Current Diagnostic and Treatment Strategies for Eosinophilic Esophagitis. Gastroenterol Hepatol (N Y) (2017) 0.75
Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology (2007) 9.05
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA (2004) 6.06
Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA (2009) 5.61
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos (2004) 3.04
Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol (2006) 2.92
Overprescribing proton pump inhibitors. BMJ (2008) 2.53
Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol (2007) 2.36
Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med (2002) 2.14
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst (2004) 2.02
Interleukin-8 induces neutrophil transendothelial migration. Immunology (1991) 2.01
Oxygen, ischemia and inflammation. Acta Physiol Scand Suppl (1986) 1.63
Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter (1998) 1.61
A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem (2003) 1.57
Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut (1994) 1.51
A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther (2000) 1.48
Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut (1992) 1.46
Regulation of the V-ATPase along the endocytic pathway occurs through reversible subunit association and membrane localization. PLoS One (2008) 1.38
Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res (2006) 1.37
Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep (2008) 1.25
Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis. Int J Mol Med (2006) 1.24
Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am J Gastroenterol (2009) 1.21
Inhibition of neutrophil oxidative metabolism by lysosomotropic weak bases. Blood (1986) 1.19
Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-reperfusion in rats. World J Gastroenterol (2004) 1.17
The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab (2009) 1.16
Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med (1996) 1.11
Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun (2006) 1.10
Effect of inhibitors of Na+/H+-exchange and gastric H+/K+ ATPase on cell volume, intracellular pH and migration of human polymorphonuclear leucocytes. Br J Pharmacol (1998) 1.09
Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology (1992) 1.03
Antioxidant properties of omeprazole. FEBS Lett (1996) 1.02
Differential engagement of modules 1 and 4 of vascular cell adhesion molecule-1 (CD106) by integrins alpha4beta1 (CD49d/29) and alphaMbeta2 (CD11b/18) of eosinophils. J Biol Chem (2006) 1.02
Lansoprazole inhibits oxygen-derived free radical production from neutrophils activated by Helicobacter pylori. J Clin Gastroenterol (1995) 1.01
Treatment of eosinophilic esophagitis: overview, current limitations, and future direction. Am J Gastroenterol (2008) 0.99
Human esophageal microvascular endothelial cells respond to acidic pH stress by PI3K/AKT and p38 MAPK-regulated induction of Hsp70 and Hsp27. Am J Physiol Cell Physiol (2006) 0.99
The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells. Eur J Pharmacol (2005) 0.98
Immunology. Unraveling gut inflammation. Science (2006) 0.98
Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther (2004) 0.97
Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci (1999) 0.96
Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol (2000) 0.96
Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol (2005) 0.96
The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole. Biochim Biophys Acta (1995) 0.93
Integrated approach to treatment of children and adults with eosinophilic esophagitis. Gastrointest Endosc Clin N Am (2008) 0.93
Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. Dig Dis Sci (1999) 0.92
Effects of esomeprazole on glutathione levels and mitochondrial oxidative phosphorylation in the gastric mucosa of rats treated with indomethacin. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.85
A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther (2008) 0.83
The inhibitory effects of H+ K+ ATPase inhibitors on human neutrophils in vitro: restoration by a K+ ionophore. Inflamm Res (2007) 0.82
Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol (2006) 0.82
Omeprazole in ulcerative colitis. Lancet (1994) 0.80
Effect of the H, K-ATPase inhibitor, esomeprazole magnesium, on gut total antioxidant capacity in mice. J Nutr Biochem (2004) 0.79
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Might the use of acid-suppressive medications predispose to the development of eosinophilic esophagitis? Am J Gastroenterol (2009) 3.65
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol (2007) 2.36
Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut (2012) 2.00
Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol (2007) 1.92
The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol (2012) 1.81
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80
Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology (2009) 1.72
Barrett's esophagus. N Engl J Med (2014) 1.67
Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol (2008) 1.53
Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol (2011) 1.50
Is genomic evaluation feasible in endoscopic studies of Barrett's esophagus? A pilot study. Gastrointest Endosc (2006) 1.49
Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology (2002) 1.46
Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci (2012) 1.45
Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One (2012) 1.43
Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut (2009) 1.20
Tissue remodeling in eosinophilic esophagitis. Am J Physiol Gastrointest Liver Physiol (2012) 1.20
Trains, tracks, and promotion in an academic medical center. Gastroenterology (2011) 1.18
Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology (2010) 1.18
Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 1.17
In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. Cancer Res (2009) 1.16
Hallmarks of cancer progression in Barrett's oesophagus. Lancet (2002) 1.13
Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol (2005) 1.08
Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus (2008) 1.07
Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway. Cancer Res (2009) 1.07
NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-kappaB in Barrett's esophageal adenocarcinoma cells. J Biol Chem (2007) 1.06
Fatal hyperammonemic encephalopathy after gastric bypass surgery. Am J Med (2008) 1.03
TNFalpha activates c-Jun amino terminal kinase through p47(phox). Exp Cell Res (2002) 1.01
Pneumatic dilation and laparoscopic Heller's myotomy equally effective for achalasia. N Engl J Med (2011) 1.01
A systematic review of the risk of perforation during esophageal dilation for patients with eosinophilic esophagitis. Dig Dis Sci (2010) 0.99
Managing Barrett's oesophagus. BMJ (2003) 0.98
Acid-induced p16 hypermethylation contributes to development of esophageal adenocarcinoma via activation of NADPH oxidase NOX5-S. Am J Physiol Gastrointest Liver Physiol (2010) 0.98
Prohibitin 1 modulates mitochondrial stress-related autophagy in human colonic epithelial cells. PLoS One (2012) 0.97
Re-examination of the cost-effectiveness of surgical versus medical therapy in patients with gastroesophageal reflux disease: the value of long-term data collection. Am J Gastroenterol (2004) 0.96
Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett (2008) 0.96
Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations. PLoS One (2010) 0.95
In non-neoplastic Barrett's epithelial cells, acid exerts early antiproliferative effects through activation of the Chk2 pathway. Cancer Res (2007) 0.95
Integrated approach to treatment of children and adults with eosinophilic esophagitis. Gastrointest Endosc Clin N Am (2008) 0.93
Hedgehog signaling regulates FOXA2 in esophageal embryogenesis and Barrett's metaplasia. J Clin Invest (2014) 0.92
Prohibitin attenuates colitis-associated tumorigenesis in mice by modulating p53 and STAT3 apoptotic responses. Cancer Res (2012) 0.92
Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol (2010) 0.92
Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol (2013) 0.92
Acid increases MAPK-mediated proliferation in Barrett's esophageal adenocarcinoma cells via intracellular acidification through a Cl-/HCO3- exchanger. Am J Physiol Gastrointest Liver Physiol (2005) 0.91
microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6. Gut (2012) 0.91
Mechanisms of oxidant production in esophageal squamous cell and Barrett's cell lines. Am J Physiol Gastrointest Liver Physiol (2007) 0.90
Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists. Am J Surg Pathol (2016) 0.88
Biology of Barrett's esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am (2011) 0.88
Cellular origins and molecular mechanisms of Barrett's esophagus and esophageal adenocarcinoma. Ann N Y Acad Sci (2013) 0.88
Repeated exposure to acid and bile selectively induces colonic phenotype expression in a heterogeneous Barrett's epithelial cell line. Lab Invest (2008) 0.88
All trans-retinoic acid induces apoptosis via p38 and caspase pathways in metaplastic Barrett's cells. Am J Physiol Gastrointest Liver Physiol (2006) 0.88
High-frequency probe ultrasonography has limited accuracy for detecting invasive adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: a case series. Am J Gastroenterol (2006) 0.87
Biomarkers and molecular diagnosis of gastrointestinal and pancreatic neoplasms. Nat Rev Gastroenterol Hepatol (2010) 0.87
Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. Ann N Y Acad Sci (2013) 0.86
Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology (2002) 0.86
Multilayered epithelium in mucosal biopsy specimens from the gastroesophageal junction region is a histologic marker of gastroesophageal reflux disease. Am J Surg Pathol (2009) 0.85
Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol (2012) 0.85
Stem cells in Barrett's esophagus: HALOs or horns? Gastrointest Endosc (2008) 0.84
p47phox participates in activation of RelA in endothelial cells. J Biol Chem (2003) 0.83
MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer. Dig Dis Sci (2013) 0.82
Intestinal metaplasia at the gastroesophageal junction: Barrett's, bacteria, and biomarkers. Am J Gastroenterol (2003) 0.82
Banding without resection (endoscopic mucosal ligation) as a novel approach for the ablation of short-segment Barrett's epithelium: results of a pilot study. Am J Gastroenterol (2007) 0.81
Development and characterization of a surgical mouse model of reflux esophagitis and Barrett's esophagus. J Gastrointest Surg (2013) 0.81
Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev (2004) 0.81
Activation of the esophagin promoter during esophageal epithelial cell differentiation. Genomics (2002) 0.81
Upper gastrointestinal bleeding in a patient with AIDS. Nat Clin Pract Gastroenterol Hepatol (2006) 0.81
Surgery for gastroesophageal reflux disease: esophageal impedance to progress? Clin Gastroenterol Hepatol (2009) 0.80
Bringing GERD Management up to PAR-2. Am J Gastroenterol (2010) 0.78
Phospho-mTOR is not upregulated in metastatic SDHB paragangliomas. Eur J Clin Invest (2013) 0.78
Acid burn or cytokine sizzle in the pathogenesis of heartburn? J Gastroenterol Hepatol (2013) 0.77
Molecular markers and genetics in cancer development. Surg Oncol Clin N Am (2009) 0.77
Biomarkers and photodynamic therapy for Barrett's esophagus: time to FISH or cut bait? Gastroenterology (2008) 0.77
Laryngopharyngeal reflux: a cause of faulty phonation or a faulted, phony diagnosis? Clin Gastroenterol Hepatol (2006) 0.77
GERD is associated with shortened telomeres in the squamous epithelium of the distal esophagus. Am J Physiol Gastrointest Liver Physiol (2007) 0.77
Barrett's Esophagus without dysplasia: wait or ablate? Dig Dis Sci (2011) 0.77
Gastrointestinal sensitivity and gastroesophageal reflux disease. Ann N Y Acad Sci (2013) 0.77
Barrett's esophagus: is the goblet half empty? Clin Gastroenterol Hepatol (2012) 0.76
Induction of colonic epithelial cell apoptosis by p47-dependent oxidants. FEBS Lett (2003) 0.76
Esophageal human β-defensin expression in eosinophilic esophagitis. Pediatr Res (2013) 0.75
Buried (but not dead) Barrett's metaplasia: tales from the crypts. Gastrointest Endosc (2012) 0.75
Introduction to the "GRG Scholars Invited Reviews". Dig Dis Sci (2013) 0.75
Introduction to the "GRG profiles and perspectives" series. Dig Dis Sci (2014) 0.75
Cardiac mucosa, Barrett's oesophagus and cancer of the gastro-oesophageal junction: what's in a name? Gut (2016) 0.75
Challenges of NIH funding for young investigators: how the AGA is filling the gap via the AGA Research Foundation. Clin Gastroenterol Hepatol (2014) 0.75
Gain of allelic gene expression for IGF-II occurs frequently in Barrett's esophagus. Am J Physiol Gastrointest Liver Physiol (2005) 0.75
Assessment of oxidants in mitogen-activated protein kinase activation. Methods Enzymol (2002) 0.75
Causes, evaluation, and consequences of eosinophilic esophagitis. Ann N Y Acad Sci (2013) 0.75
Challenges of NIH funding for young investigators: how the AGA is filling the gap via the AGA research foundation. Gastroenterology (2014) 0.75
Unique Clinical Features of Los Angeles Grade D Esophagitis Suggest That Factors Other Than Gastroesophageal Reflux Contribute to its Pathogenesis. J Clin Gastroenterol (2017) 0.75